GTS Securities’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-306,800
Closed -$8.88M – 3271
2024
Q3
$8.88M Buy
306,800
+21,200
+7% +$618K 0.02% 562
2024
Q2
$7.99M Sell
285,600
-113,400
-28% -$3.12M 0.02% 596
2024
Q1
$11.1M Buy
399,000
+9,300
+2% +$258K 0.02% 461
2023
Q4
$11.2M Buy
389,700
+296,000
+316% +$8.95M 0.02% 557
2023
Q3
$3.11M Buy
+93,700
New +$3.31M 0.01% 1213

Other funds holding PFE

GTS Securities's PFE Position: Q3 2026 in Review

GTS Securities increased its Pfizer (PFE) stake by 248% in Q3 2026, buying an estimated $936K and bringing the position to 49,369 shares worth $1.41M. The position accounts for 0.03% of the portfolio, ranked #393.

GTS Securities first reported a position in PFE in Q2 2023 and has held it in 13 quarters since. The position peaked at $41.8M in Q4 2023. 2,918 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • GTS Securities held 49,369 shares of Pfizer worth $1.41M as of Q3 2026.
  • GTS Securities bought 35,193 Pfizer shares in Q3 2026, an estimated $936K.
  • Pfizer made up 0.03% of GTS Securities's portfolio in Q3 2026, its #393 holding.
  • GTS Securities first reported a position in Pfizer in Q2 2023 and has held it in 13 quarters since.
  • GTS Securities's Pfizer position peaked at $41.8M in Q4 2023.
  • 2,918 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.